Menopause is a gradual and natural transitional phase of adjustment between the active and inactive ovarian function and occupies several years of a women's life and involves biological and psychological changes adjustments. The present clinical trial was designed as per Ayurveda clinical trials protocol to evaluate the efficacy of Ashokarishta, Ashwagandha Churna and Praval Pishti in the management of menopausal syndrome. It was directed by Central Council for Research in Ayurvedic Sciences as randomized open clinical trial. Total 52 patients were registered in the study, out of which 51 patients completed the study. Specialized rating scales like Kupperman Index Score as well as Menopause Rating Scale (MRS) and Menopause Specific Quality of Life (MENQOL) questionnaires were adopted for diagnostic as well as assessment criteria. The effects were examined based on MRS and MENQOL. Results were analyzed statistically using Wilcoxon matched paired test and ‘t’ test. Highly significant (P < 0.01) reduction was found in the symptoms of MRS as well as MENQOL. Finally, it can be stated that combined treatment of above drugs gives better result in both somatic as well as psychological complaints in women with mild to moderate symptoms of menopausal syndrome.
The desire to have a healthy progeny is innate and very intense in every livingbeing. The hectic life and tremendous stress in daily life has made the conception and continuation of pregnancy till term very difficult. Anemia is one of the common disease conditions, which affects a pregnant woman. In Ayurvedic classics anemia in pregnancy is taken under the Rasa Pradoshajavikara. It is clear that Garbhavasthajanyapandu occurs due to the fetal demands and improper functioning of the Rasadhatu leading to malnourishment of the body. A total of 26 patients were registered from out-patient department of Streeroga and Prasutitantra, out of which four patients discontinued. The remaining 22 patients were randomly divided into two groups; Group A (n-12) Pandughnivati two tablets of 500 mg tds and Group B (n-10) Dhatrilauhavati one tablet of 500 mg tds. Dhatrilauhavati was selected for the present study due to its Pandughna, Prinana, Raktaprasadana properties. In the present study, Pandughnivati a compound formulation developed by AYUSH department was administered for patients of group A. The results revealed that the over all clinical improvement was better in patients of Group B when compared to Group A. Hence it was concluded that Dhatrilauhavati was effective in treating anemia during pregnancy.
Poly Cystic Ovarian Disease (PCOD) is a complex disorder affecting 5-15% women in their reproductive age and related to ovarian dysfunction, characterized by menstrual irregularities, hyperandrogonism, obesity, and infertility. In Ayurveda, these symptoms are found under various conditions, caused by vitiated Vata and Kapha. Pathadi Kwatha and Shatapushpa Taila Matra Basti were studied in the current attempt to evaluate their comparative efficacy in cases of PCOD. Total 34 patients of PCOD were registered among which, 32 had completed the treatment of 2 months. They were randomly divided in to three groups. In group A Pathadi Kwatha (10 g, bid) and Shatapushpa Taila Matra Basti (60 ml for 7 days after cessation of menses for 2 consecutive cycles) were administered. In group B only Basti, whereas in group C capsules of roosted wheat flour were administered. Better results were obtained in group A especially in menstrual irregularities, achieving follicular growth and in weight reduction.
Premature contraction of the uterus is the very first sign of premature labour, which is followed by progressive changes in cervix such as effacement and dilatation. Four or more uterine contractions with or without pain per hour is a major biophysical predictor of preterm labour. According to the WHO statistics, every year, an estimated 15 million babies are born preterm and this number is rising. Although tocolytic agents are used to suppress premature contractions and prevent preterm labour, it is not proven to be efficacious in preventing preterm birth or reducing neonatal mortality or morbidity. As per Ayurveda, Akala Prasava (preterm labour) results due to the malfunctioning of Apana Vata (a type of Vata Dosha which is responsible for the excretory action). Basti (medicated enema therapy) is considered the best for managing the deranged Apana Vata. Basti is also indicated in Garbhini Paricharya (routine antenatal care) after completion of seven months of pregnancy. In this present case study, Shatavaryadi Ksheerapaka Basti (medicated enema prepared along with milk) was administered in a 28 year old second gravida patient of 33 weeks gestation with premature contractions, wherein isoxsuprine hydrochloride proved to be ineffective. Per-rectal Basti with 450 ml Shatavaryadi Ksheerapaka administered for 2 consecutive days was found to be effective in preventing the uterine contractions and further advancement to preterm labour. The drugs in Shatavaryadi Ksheerapaka Basti possess antioxytocic and vasodilating properties which may effectively curtailed the progress of premature contractions.
Introduction:India is one of the countries with high prevalence of anemia during pregnancy. Anemia in pregnancy is multifactorial. Iron deficiency anemia is the most common conditions in a pregnant woman. As per ayurvedic classics, this condition occurs due to improper Rasa Dhatu in mother and continuously increasing fetal demands and is considered as Rasa Pradoshajavikara. A large number of Lauha preparations have been used widely for centuries to cure Anemia.Aim:To evaluate efficacy of Punarnava Mandura and Dhatri Lauha on Garbhini Pandu.Materials and Methods:A total 24 pregnant women with symptoms of Garbhini Pandu were randomly divided into two groups (A and B). In Group A (n = 15) Punarnava Mandura, two tablets (each of 500 mg) thrice a day with one cup (100 ml) of buttermilk and in Group B (n = 9) Dhatri Lauha, two tablets (each of 500 mg) thrice a day with luke warm water were administered for 90 days. The assessment was done with subjective parameters such as pallor, general weakness, dyspnea, etc., and objective parameters such as hematological parameters. Results were statistically analyzed using Student's t-test.Results:The results revealed that overall clinical improvement was better in Group A when compared to Group B. Hemoglobin was increased in patients of Group A, which was statistically significant. No adverse drug reaction was observed during the treatment period.Conclusion:Punarnava Mandura is more effective on Garbhini Pandu in comparison to Dhatri Lauha.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.